Interestingly, targeting of endothelial FAK activity improved the efficacy of DNA-damaging chemotherapeutics, providing proof-of-principle for normalization of tumor vasculature as an adjuvant approach in cancer therapies (138). This evidence concerns the gene PTK2 and neoplasm.